Drugs / AMG0001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04267640 | Jan 2020 → Jul 2022 | limb ischemia, peripheral arterial disease, ulcer of lower limbs | AnGes USA, Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02144610 | Nov 2014 → Nov 2016 | limb ischemia | AnGes USA, Inc. | Terminated | Mixed |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00189540 Comparator | Aug 2005 → Jul 2008 | arterial occlusion, ischemic disease, peripheral vascular disease, ulcer disease | AnGes USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00060892 Comparator | Apr 2003 → May 2006 | arterial occlusion, limb ischemia, peripheral vascular disease | AnGes USA, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG0001 | “The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the...” NCT00060892 ↗3“The primary goals of this study evaluating AMG0001 administration in CLI subjects will be to investigate the efficacy and safety of AMG0001.” NCT00189540 ↗ |
| Known as | HGF plasmid | “This is a double-blind, randomized, placebo-controlled, phase 3, multinational, multicenter study of AMG0001 (HGF plasmid) in subjects with Critical Limb Ischemia (CLI).” NCT02144610 ↗ |
| Modality | Other / unclassified | “HGF transferred via plasmid vector” NCT00060892 ↗ |
| Route | Intramuscular | “Intramuscular injections into index leg on Days 0, 14, and 28” NCT00060892 ↗ |
| Target | HGF | “a plasmid encoding human HGF (hepatocyte growth factor)” PMID 41186002 ↗ Nov 2025 |